US-based biopharmaceutical company Sunovion Pharmaceuticals has reported positive top-line results from its Phase III clinical trial of latuda (lurasidone HCl) for the treatment of depression associated with bipolar I disorder (bipolar depression).

Latuda is a part of atypical anti-psychotics class, which are thought to work by modifying the levels of neurotransmitters dopamine and serotonin.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It is being developed to treat patients with bipolar depression when used alone or with lithium or valproate in adults, as well as schizophrenia in adults and adolescents 13 to 17 years of age.

The results from the trial showed statistically significant and clinically meaningful improvement in symptoms of bipolar depression when compared to placebo, at both the primary and secondary endpoints.

"We are encouraged by these top-line results that demonstrate the potential of LATUDA to help children and adolescents with bipolar depression."

The randomised, double-blind, placebo-controlled, parallel-group, multi-regional Phase III trial evaluated latuda for six weeks, in children and adolescents aged 10 to 17 years with bipolar depression.

See Also:

Sunovion executive vice-president and chief medical officer Antony Loebel said: “There are few treatment options for bipolar depression in this population.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are encouraged by these top-line results that demonstrate the potential of LATUDA to help children and adolescents with bipolar depression.”

The trial's primary efficacy endpoint was change from baseline to week six on the children depression rating scale revised (CDRS-R) total score, while the secondary endpoint was change from baseline to week six on the clinical global impression-bipolar version, severity of illness (CGI-BP-S) score for depression.

Latuda was found to be generally well tolerated, with minimal effects on weight and metabolic parameters.